TY  - JOUR

T1  - Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

JO  - The Lancet Oncology

PY  - 2017/07/01

AU  - Cameron D

AU  - Morden JP

AU  - Canney P

AU  - Velikova G

AU  - Coleman R

AU  - Bartlett J

AU  - Agrawal R

AU  - Banerji J

AU  - Bertelli G

AU  - Bloomfield D

AU  - Brunt AM et al

ED  - 

DO  - DOI: 10.1016/s1470-2045(17)30404-7

PB  - Elsevier BV

VL  - 18

IS  - 7

SP  - 929

EP  - 945

Y2  - 2025/10/10

ER  -